Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 95 peer-reviewed journal articles Updated

Understanding Your Child's Osteosarcoma Diagnosis

At a Glance

Osteosarcoma is a rare bone cancer most commonly found in teenagers. For localized cases, five-year survival rates are 60% to 70%. The standard of care involves chemotherapy and limb-salvage surgery performed by a multidisciplinary team at a specialized sarcoma center.

Receiving an osteosarcoma diagnosis for your child or teenager is an overwhelming experience. While it is a serious condition, it is also a disease that modern medicine has developed highly structured and effective protocols to fight. Understanding the nature of this rare cancer and the standard of care can help you move from a place of fear to a place of focused action.

Understanding Osteosarcoma

Osteosarcoma is a high-grade malignant bone tumor, meaning it is a type of cancer that begins in the cells that form bone [1]. It is most commonly diagnosed in adolescents and young adults (AYA), often occurring during the rapid growth spurts of the teenage years [2][3].

In this condition, the body’s bone-forming cells begin to grow uncontrollably, typically at the ends of long bones like the femur (thigh bone), tibia (shin bone), or humerus (upper arm bone) [1]. While the exact cause is often unknown, research highlights a complex “crosstalk” between the bone environment and the immune system that allows these cells to multiply and potentially spread to other areas, most commonly the lungs [4][1].

Grounding Facts for Parents

When facing a new diagnosis, it is helpful to anchor your perspective with these three evidence-based facts:

  1. High Survival Rates for Localized Disease: For children and adolescents whose cancer is localized (has not spread beyond the original bone), 5-year survival rates are approximately 60% to 70% [1][5]. Younger patients and those with specific tumor types often have even more favorable outlooks [6][7].
  2. Limb-Salvage is Now the Standard: Advances in surgery mean that the vast majority of patients can undergo limb-salvage surgery (removing the tumor while keeping the limb) rather than amputation [2][8]. These procedures provide survival rates comparable to amputation while preserving the limb’s function and the child’s quality of life [9][8].
  3. Specialized Care Makes a Difference: Patients treated at specialized, high-volume sarcoma centers have significantly better outcomes [10]. These centers use a multidisciplinary team (a group of experts including surgeons, oncologists, and radiologists) which has been shown to improve survival and reduce the risk of the cancer returning [11][12][13].

Addressing Common Misunderstandings

Because osteosarcoma is rare—affecting roughly 4.4 to 5 people per million in the U.S. annually—it is often misunderstood by both families and local healthcare providers [2][14].

“Growing Pains” vs. Cancer

The most common misunderstanding is attributing bone pain to “growing pains” or sports injuries [15]. While growing pains are common in teenagers, there are clear differences:

  • Location: Growing pains usually affect both legs (bilateral); osteosarcoma pain is almost always in one specific spot (unilateral) [16].
  • Timing: Growing pains often resolve by morning; osteosarcoma pain is persistent and frequently wakes a child up in the middle of the night [16].
  • Swelling: Growing pains do not cause visible swelling or a felt lump, whereas osteosarcoma often presents with a noticeable mass or swelling near a joint [1][16].

The Importance of Specialized Expertise

Due to its rarity, many local orthopedic surgeons may only see one case of osteosarcoma in their entire career. Current medical guidelines emphasize that even the initial biopsy (taking a tissue sample) must be performed by a specialized orthopedic oncologist [12][15]. A poorly placed biopsy can complicate future surgeries or even make limb-salvage impossible [12].

Centralizing care at a dedicated sarcoma center ensures your child receives the most current treatment protocols, including neoadjuvant chemotherapy (chemotherapy given before surgery to shrink the tumor) and highly precise surgical planning [8][17].

Next Steps

Navigate through the pages below to learn more about each step of the osteosarcoma journey:

01

Symptoms and Warning Signs: Distinguishing Cancer from Common Injuries

Learn the early warning signs of osteosarcoma and how to distinguish them from growing pains or sports injuries. Understand when bone pain requires an MRI.

02

Biology and Diagnosis: Why the "How" and "Who" Matter

Understand your child's osteosarcoma diagnosis. Learn about the role of TP53 and RB1 genes, malignant osteoid, imaging, and why the biopsy surgeon matters.

03

Pathology and Huvos Grading: Your Treatment "Report Card"

Understand your child's osteosarcoma pathology report and Huvos grading. Learn why 90% tumor necrosis is crucial and what margin status means for treatment.

04

Standard of Care: Chemotherapy and Surgical Options

Learn about standard osteosarcoma treatment, including the 8-10 month MAP chemotherapy regimen, limb-salvage surgery options, and heart protection.

05

Building Your Care Team: The Power of Specialized Expertise

Learn how to build an expert osteosarcoma care team for your child. Understand the role of multidisciplinary specialists and how to prepare for consultations.

06

Survivorship: Navigating the Road Ahead and Long-Term Monitoring

Learn about osteosarcoma survivorship and long-term monitoring. Discover the standard surveillance schedule, late effects of MAP therapy, and scanxiety tips.

Common questions in this guide

How can I tell the difference between growing pains and osteosarcoma?
Growing pains usually affect both legs and disappear by morning without causing swelling. In contrast, osteosarcoma pain is typically in one specific spot, often wakes a child up at night, and may cause a noticeable lump or swelling near a joint.
What is the survival rate for childhood osteosarcoma?
For children and teenagers with localized osteosarcoma—meaning the cancer has not spread beyond the original bone—the five-year survival rate is approximately 60% to 70%. Younger patients can sometimes have even more favorable outcomes.
What is limb-salvage surgery?
Limb-salvage surgery is a procedure that removes the bone tumor while saving the arm or leg, avoiding the need for amputation. This approach provides survival rates similar to amputation while preserving the limb's function and the child's quality of life.
Who should perform the biopsy for suspected osteosarcoma?
Current medical guidelines state that the initial biopsy must be performed by a specialized orthopedic oncologist. If a biopsy is placed poorly by someone inexperienced with osteosarcoma, it can complicate future surgeries and even make limb-salvage impossible.
Why is it important to go to a specialized sarcoma center?
Because osteosarcoma is very rare, many local doctors have little experience treating it. High-volume sarcoma centers have dedicated multidisciplinary teams, which research shows significantly improves survival rates and reduces the risk of the cancer returning.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does our child’s diagnosis include the 'localized' or 'metastatic' classification, and how does that guide the first step of treatment?
  2. 2.Who are the members of the multidisciplinary team (MDT) managing our child's care, and how many osteosarcoma cases do they treat each year?
  3. 3.Can you confirm that the biopsy will be performed by the same orthopedic oncologist who would eventually perform the definitive surgery?
  4. 4.What specific red flags should we look for that might indicate the treatment needs to be adjusted?
  5. 5.What is the plan for protecting our child's long-term heart and kidney health during chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Advances in the management of osteosarcoma.

    Bielack SS, Hecker-Nolting S, Blattmann C, Kager L

    F1000Research 2016; (5()):2767 doi:10.12688/f1000research.9465.1.

    PMID: 27990273
  2. 2

    Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes.

    Nie Z, Peng H

    Oncology letters 2018; (16(5)):6502-6514 doi:10.3892/ol.2018.9453.

    PMID: 30405789
  3. 3

    Incidence and age- and site-specific characteristics of osteosarcoma: a population-based study using National Cancer Registry 2016-2019.

    Ogura K, Morizane C, Satake T, et al.

    Japanese journal of clinical oncology 2025; (55(9)):1037-1045 doi:10.1093/jjco/hyaf086.

    PMID: 40459219
  4. 4

    The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.

    Cascini C, Chiodoni C

    Cells 2021; (10(7)) doi:10.3390/cells10071668.

    PMID: 34359840
  5. 5

    Development and validation of nomogram based on miR-203 and clinicopathological characteristics predicting survival after neoadjuvant chemotherapy and surgery for patients with non-metastatic osteosarcoma.

    Cheng D, Qiu X, Zhuang M, et al.

    Oncotarget 2017; (8(57)):96935-96944 doi:10.18632/oncotarget.18534.

    PMID: 29228583
  6. 6

    Evaluating and Predicting the Probability of Death in Patients with Non-Metastatic Osteosarcoma: A Population-Based Study.

    Huang R, Xian S, Shi T, et al.

    Medical science monitor : international medical journal of experimental and clinical research 2019; (25()):4675-4690 doi:10.12659/MSM.915418.

    PMID: 31231119
  7. 7

    Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.

    Fukushima T, Ogura K, Akiyama T, et al.

    BMC musculoskeletal disorders 2018; (19(1)):297 doi:10.1186/s12891-018-2217-1.

    PMID: 30121085
  8. 8

    A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes.

    He X, Gao Z, Xu H, et al.

    Journal of orthopaedic surgery and research 2017; (12(1)):5 doi:10.1186/s13018-016-0500-0.

    PMID: 28086937
  9. 9

    Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis.

    Papakonstantinou E, Stamatopoulos A, I Athanasiadis D, et al.

    Journal of bone oncology 2020; (25()):100319 doi:10.1016/j.jbo.2020.100319.

    PMID: 33088699
  10. 10

    Surgery at specialised sarcoma centres improves patient outcomes - A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party.

    Hong AM, Sundaram A, Perianayagam G, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2023; (49(9)):106951 doi:10.1016/j.ejso.2023.06.003.

    PMID: 37301636
  11. 11

    Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

    Blay JY, Honoré C, Stoeckle E, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2019; (30(7)):1143-1153 doi:10.1093/annonc/mdz124.

    PMID: 31081028
  12. 12

    Osteosarcoma.

    Beird HC, Bielack SS, Flanagan AM, et al.

    Nature reviews. Disease primers 2022; (8(1)):77 doi:10.1038/s41572-022-00409-y.

    PMID: 36481668
  13. 13

    Medical Care and Survival of Soft-Tissue and Bone Sarcoma Patients: Results and Methodological Aspects of a German Subnational Cohort Study Based on Administrative Healthcare Data.

    Schoffer O, Roessler M, Datzmann T, et al.

    Oncology research and treatment 2021; (44(3)):103-110 doi:10.1159/000513178.

    PMID: 33378758
  14. 14

    Understanding osteosarcomas.

    Simpson E, Brown HL

    JAAPA : official journal of the American Academy of Physician Assistants 2018; (31(8)):15-19 doi:10.1097/01.JAA.0000541477.24116.8d.

    PMID: 29979330
  15. 15

    UK guidelines for the management of bone sarcomas.

    Gerrand C, Athanasou N, Brennan B, et al.

    Clinical sarcoma research 2016; (6()):7 doi:10.1186/s13569-016-0047-1.

    PMID: 27148438
  16. 16

    Efferocytosis-associated transcriptomic patterns characterize prognosis and immune landscape in osteosarcoma.

    Song X, Tou X, Li L, et al.

    Journal of bone oncology 2026; (57()):100743 doi:10.1016/j.jbo.2026.100743.

    PMID: 41631009
  17. 17

    PATIENTS WITH SOFT TISSUE SARCOMA AFTER TREATMENT BY NON ORTHOPEDIC ONCOLOGIC SURGEONS: EPIDEMIOLOGICAL PROFILE, STAGING, AND THERAPEUTIC CHALLENGES.

    do Couto FB, Yonamine ES, Magno FG, et al.

    Acta ortopedica brasileira 2026; (34(1)):e293900 doi:10.1590/1413-785220263401e293900.

    PMID: 41696555

This page provides an overview of childhood osteosarcoma for educational purposes only. Always consult a pediatric orthopedic oncologist at a specialized sarcoma center for medical advice and treatment planning.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.